3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
228
Neoplasm Metastasis
17
Breast Neoplasms, Male
7
Breast Diseases
7
Neoplasms
6
Carcinoma, Intraductal, Noninfiltrating
4
Recurrence
3
Obesity
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Neoplasms by Site
2
Bulbo-Spinal Atrophy, X-Linked
2
Arthralgia
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Primary Breast Cancer ER+ve
1
Premenopausal Breast Cancer
1
Post Menopausal Women With Early Breast Cancer
1
Patient Acceptance of Health Care
1
Pain
1
Interventions
Fulvestrant
10
Letrozole
4
Alpelisib
4
ribociclib
3
palbociclib
3
Paclitaxel
2
NVP-BKM120
2
volagidemab
1
serabelisib
1
sapanisertib
1
olaparib
1
liposomal doxorubicin
1
gedatolisib
1
exemestane
1
dapagliflozin
1
capivasertib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Secretin
1
STX-478
1
Metformin
1
Lomustine
1
Leuprolide
1
Irinotecan
1
Imlunestrant
1
Goserelin
1
Gemcitabine
1
Drug Therapy
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
exemestane
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled